Skip to main content

Gelteq Ltd

corporate_fare Company Profile

Gelteq Ltd

GELS·NASDAQ·Life Sciences·CIK 0001920092

Gelteq Ltd is a biotechnology company headquartered in Melbourne, Australia, developing a proprietary ingestible gel-based delivery platform for pharmaceutical, consumer health and animal health applications. The company's delivery technology is designed to improve how active pharmaceutical ingredients (APIs) are formulated, stabilized and absorbed by the body. Gelteq specializes in research and development, product creation and manufacturing for partners across the pharmaceutical, consumer health and animal health markets. Its Ordinary Shares are listed on the Nasdaq Capital Market under the symbol "GELS." The Gelteq platform is being developed to address formulation and delivery challenges associated with conventional dosage formats, providing an alternative ingestible delivery format for active ingredients that may be difficult to formulate, administer or differentiate using conventional dosage forms. The platform is not dependent on a single active ingredient, therapeutic indication or commercial customer. The company cites industry context for its technology: approximately 40% to 60% of marketed drugs are poorly soluble, and up to 90% of drug discovery candidates experience solubility limitations. Gelteq also points to lifecycle management opportunities, noting that more than US$230 billion in pharmaceutical revenue is expected to face generic and biosimilar competition, with branded products potentially experiencing revenue declines of up to 90% following patent expiry and generic market entry. On ease of administration, approximately 40% of consumers report difficulty swallowing pills, and the company believes gel-based dosage forms may help address such challenges for certain consumers and patient populations, including individuals who have difficulty swallowing pills.

Gelteq Ltd (NASDAQ:GELS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for GELS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 9/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for GELS spans 20-F, 6-K.

Recent high-impact activity:

  • Gelteq FY2026: AUD$25.8M Loss, Full Intangible Write-Down, Going-Concern Warning
  • Gelteq Secures $2.5M in Critical Convertible Debt Financing After Shareholder Approval
  • Gelteq Reports Dire Cash Position and Worsening Working Capital Deficit; Details Highly Dilutive Convertible Debt Terms
  • Gelteq to Launch Human Clinical Trials Next Quarter, Expands Pipeline into Diabetes and Peptides
  • Gelteq's Gel-Based Tech Validated in Animal Trials, Boosting Partnership Prospects

Financial Snapshot

Fiscal year ended June 30, 2026
Net Income
-25.78M
Diluted EPS
2.37
Op. Cash Flow
-1.91M
Operating Income
-24.94M
Cash & Equivalents
132.58K
Total Debt
2.1M
Debt / Equity
-0.28×
Source: 20-F · filed 2026-11-16 · accession 0001213900-26-120645

Short Interest & Short Volume

2.08 days to cover

FINRA reported short interest of 228,185 shares in GELS as of the October 30, 2026 settlement, a 27.5% decrease from the prior period — about 2.1 days to cover at its recent average daily volume. On November 20, 2026, 47.2% of GELS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)228,185 shares as of October 30, 2026
Change vs prior period▼ 27.5%
Days to cover2.08 at avg daily volume of 109,814
Daily short volume (FINRA facilities)47.2% of 18,161 shares on November 20, 2026
5-day average short volume26.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for GELS, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.

Shareholder Approval for Debt Financing · Second Tranche of Debt Financing Closed

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

GELS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with G →
$0.2909 +7.70% today
52-week range · as of 2026-11-16 $0.2909 – $2.01
Market cap
$2.89M
Volume
26.3K (0.4× avg)
3-mo avg 65.8K
Live data · 2026-11-21 05:21 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GELS - Latest Insights

GELS
Nov 16, 2026, 4:10 PM EST
Filing Type: 20-F
Importance Score:
9
Price at Filing: $0.3589
Real-time Price: $0.2909 info
Change: -$0.068 (-19%) info
Market Cap: $2.893M info
GELS
Jul 02, 2026, 5:59 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.5601
Real-time Price: $0.2909 info
Change: -$0.2692 (-48%) info
Market Cap: $2.893M info
GELS
Jun 30, 2026, 5:29 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.659
Real-time Price: $0.2909 info
Change: -$0.3681 (-56%) info
Market Cap: $2.893M info
GELS
Jun 17, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.20
Real-time Price: $0.2909 info
Change: -$0.9091 (-76%) info
Market Cap: $2.893M info
GELS
Jun 12, 2026, 12:30 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.9799
Real-time Price: $0.2909 info
Change: -$0.689 (-70%) info
Market Cap: $2.893M info
GELS
Jun 04, 2026, 9:08 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.550
Real-time Price: $0.2909 info
Change: -$0.2591 (-47%) info
Market Cap: $2.893M info
GELS
Jun 02, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.484118
Real-time Price: $0.2909 info
Change: -$0.193218 (-40%) info
Market Cap: $2.893M info
GELS
May 26, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.422
Real-time Price: $0.2909 info
Change: -$0.1311 (-31%) info
Market Cap: $2.893M info
GELS
May 20, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.391
Real-time Price: $0.2909 info
Change: -$0.1001 (-26%) info
Market Cap: $2.893M info
GELS
May 12, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.391
Real-time Price: $0.2909 info
Change: -$0.1001 (-26%) info
Market Cap: $2.893M info
GELS
Mar 24, 2026, 8:15 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.7102
Real-time Price: $0.2909 info
Change: -$0.4193 (-59%) info
Market Cap: $2.893M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets